Targeting the RAGE-RIPK1 binding site attenuates diabetes-associated cognitive deficits.
Level 5 - mechanism / opinion, no new human data
Preclinical animal and mechanistic study with descriptive human observational data.
PubMed 40544260 · doi:10.1186/s12974-025-03489-1
What was done
Researchers evaluated RIPK1 expression in diabetic patients with cognitive impairment and characterized the mechanistic interaction between the RIPK1 death domain and the C-terminal of RAGE (ctRAGE) in microglia. In diabetic mouse models, they investigated downstream inflammatory signaling and tested an engineered brain-targeting peptide designed to disrupt RAGE-RIPK1 binding.
What was found
RIPK1 expression was elevated in diabetic patients with cognitive impairment. In diabetic mice, ctRAGE directly bound RIPK1, promoting microglial RIPK1 phosphorylation and inflammatory cascades that caused cognitive impairment. Blocking this interaction with an engineered brain-targeting peptide inhibited RIPK1 phosphorylation, reduced neuroinflammation, preserved neuronal morphology and function, and prevented diabetes-associated cognitive decline. The abstract reported no quantitative metrics, effect sizes, or exact numbers.
Why it matters
This work identifies the RAGE-RIPK1 interaction as a driver of microglial neuroinflammation in diabetes-associated cognitive impairment and demonstrates preclinical proof-of-concept for peptide-based disruption of this complex.
Limits
Findings rely predominantly on mouse and in vitro models, limiting direct applicability to human clinical outcomes. The abstract does not provide sample sizes, quantitative effect estimates, control comparisons, or pharmacokinetic parameters for the peptide intervention.
Cited by
- supports RAGE receptors on microglial cells respond to advanced glycation end products resulting from chronically elevated blood sugar.